Collegium Announces $150 Million Share Repurchase Program

Core Viewpoint - Collegium Pharmaceutical, Inc. has authorized a new share repurchase program to buy back up to $150 million in common stock, replacing a previous program that had $65 million remaining [1][2]. Financial Position and Strategy - The company emphasizes its strong financial position, which allows for flexibility in capital allocation and supports shareholder value return [2]. - Since 2021, Collegium has returned $222 million to shareholders through share repurchase programs, including $25 million from an accelerated program initiated in May 2025 [2]. Share Repurchase Program Details - The new share repurchase program is set to run through December 31, 2026, and replaces a previous program that expired on June 30, 2025 [1]. - As of March 31, 2025, Collegium had approximately 32.1 million shares outstanding [3]. Company Overview - Collegium is focused on improving the lives of individuals with serious medical conditions and has a portfolio that includes pain management medications and the recently acquired Jornay PM® for ADHD [4]. - The company's strategy involves growing its commercial portfolio with Jornay PM as a key growth driver and disciplined capital deployment [4].